# US 2008/0187536 A1 · Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0187536 A1
- Document ID: US20080187536A1
- Status: Published application
- Kind: A1
- Application number: 12/004,589
- Filed: 2007-12-20
- Published: 2008-08-07
- Earliest claimed: 2006-12-21
- Assignees: Boston Biomedical Research Institute
- Inventors: Victor Raso
- Web page: https://patentgrep.com/patent/US20080187536A1

## CPC

- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61P 35/00: Antineoplastic agents
- C07K 14/65: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/605: {MHC molecules or ligands thereof}
- A61K 2039/6075: {Viral proteins}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided is a simple and safe immunization procedure to reduce cancer incidence and increase longevity by modulating IGF-1 levels in the body. Described are cancer preventive vaccines and methods that elicit circulating antibodies specific to insulin-like growth factor 1 (IGF-1) in the body. Many cancers will be less likely to occur and spread in the absence or reduced levels of the stimulatory signals provided by IGF-1. Longevity also can be extended by immunologically lowering the level of bioavailable IGF-1 in adult animals. This prolongation of lifespan resulting from lower IGF-1 levels is produced independently of the inhibitory effects on carcinogenesis. However, the two IGF-1-mediated processes are linked mechanistically. Methods of active and passive immunization to suppress IGF-1 activity are included. Also described are methods for increasing longevity or reducing one or more symptoms of aging in a warm-blooded animal comprising administering anti-IGF-1 antibodies such that IGF-1 is inactivated or suppressed or administering IGF-1 antigen such that the animal produces endogenous antibodies to IGF-1.

## Claims

### Claim 1

A composition comprising one or more of LPV-IGF1-16, LPV-IGF22-35, LPV-IGF29-42, LPV-IGF56-70, KLH-IGF28-41, KLH-IGF22-33, KLH-IGF30-38, KLH-IGF29-42, KLH-IGF22-35, KLH-IGF1-6, KLH-IGF61-70, KLH-IGF1-16, KLH-IGF56-70, KLH-IGF30-38, KLH-IGF61-70, KLH-IGF29-42, KLH-IGF56-70, Qβ-IGF28-41, Qβ-IGF22-33, Qβ-IGF30-38, Qβ-IGF29-42, Qβ-IGF22-35, Qβ-IGF1-6, Qβ-IGF61-70, Qβ-IGF1-16, Qβ-IGF56-70, Qβ-IGF30-38, Qβ-IGF61-70, Qβ-IGF29-42 and Qβ-IGF56-70.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said composition is antigenic.

### Claim 3 (depends on 2)

The composition of claim 2, wherein said composition is used for the immunization of a mammal.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said composition, when used for the immunization of a mammal, results in the production of antibodies to IGF-1 and results in reduced unbound IGF-1 in the blood stream of said mammal.

### Claim 5 (depends on 3)

The composition of claim 3, wherein when said composition is used for the immunization of a mammal, results in the formation of an immune complex comprising the antibodies to the composition of claim 3 and IGF-1.

### Claim 6 (depends on 3, 5)

The composition of claim 5, wherein when said immune complex comprising the antibodies generated to the composition of claim 3 and IGF-1 is formed, and wherein said immune complex interferes with the binding of endogenous IGF-1 receptor-binding epitopes to the IGF-1 receptor.

### Claim 7

A method for reducing or delaying tumor growth in an adult human as compared to an untreated human, the method comprising:
a) providing one or more antigens, the antigen(s) characterized by the ability to stimulate the production of circulating antibodies which specifically bind to human IGF-1 when administered to a human under conditions appropriate for the stimulation of an immune response;
b) administering the antigen to a human under conditions appropriate for the stimulation of an immune response, thereby stimulating the production of circulating antibodies which specifically bind to human IGF-1; and
c) correlating the administration of the antigen to said human with a reduction in growth of one or more tumors.

### Claim 8 (depends on 7)

The method of claim 7, wherein said untreated human is represented by historic data.

### Claim 9 (depends on 7)

The method of claim 7 wherein the antigen is IGF-1 protein or an immunogenic portion thereof.

### Claim 10 (depends on 8)

The method of claim 8, wherein said antigen is a lipopeptide.

### Claim 11 (depends on 7)

The method of claim 7, wherein said antigen is selected from one or more of LPV-IGF1-16, LPV-IGF22-35, LPV-IGF29-42, LPV-IGF56-70, KLH-IGF28-41, KLH-IGF22-33, KLH-IGF30-38, KLH-IGF29-42, KLH-IGF22-35, KLH-IGF1-6, KLH-IGF61-70, KLH-IGF1-16, KLH-IGF56-70, KLH-IGF30-38, KLH-IGF61-70, KLH-IGF29-42, KLH-IGF56-70, Qβ-IGF28-41, Qβ-IGF22-33, Qβ-IGF30-38, Qβ-IGF29-42, Qβ-IGF22-35, Qβ-IGF1-6, Qβ-IGF61-70, Qβ-IGF1-16, Qβ-IGF56-70, Qβ-IGF30-38, Qβ-IGF61-70, Qβ-IGF29-42 and Qβ-IGF56-70.

### Claim 12 (depends on 7)

The method of claim 7, wherein the antigen is a hydrolysis transition state analog of IGF-1 protein or an immunogenic portion thereof.

### Claim 13 (depends on 7)

The method of claim 7, wherein said reduction in tumor growth is accompanied by a decrease in tumor size.

### Claim 14 (depends on 7)

The method of claim 7, wherein the antigen is encoded in a nucleotide sequence and said nucleotide sequence is administered to said adult human.

### Claim 15

A method for preventing tumor growth in an adult human as compared to untreated human(s), the method comprising:
a) providing one or more antigens, the antigen(s) characterized by the ability to stimulate the production of circulating antibodies which specifically bind to human IGF-1 when administered to a human under conditions appropriate for the stimulation of an immune response;
b) administering the antigen to an adult human under conditions appropriate for the stimulation of an immune response making an adult treated human and thereby stimulating the production of circulating antibodies which specifically bind to human IGF-1; and
c) correlating the administration of the antigen to said adult treated human with the prevention of growth of one or more tumors as compared to one or more untreated humans.

### Claim 16 (depends on 15)

The method of claim 15, wherein said untreated human is represented by historic data.

### Claim 17 (depends on 15)

The method of claim 15, wherein the antigen is IGF-1 protein or an immunogenic portion thereof.

### Claim 18 (depends on 16)

The method of claim 16, wherein said antigen is a lipopeptide.

### Claim 19 (depends on 15)

The method of claim 15, wherein said antigen is selected from one or more of LPV-IGF1-16, LPV-IGF22-35, LPV-IGF29-42, LPV-IGF56-70, KLH-IGF28-41, KLH-IGF22-33, KLH-IGF30-38, KLH-IGF29-42, KLH-IGF22-35, KLH-IGF1-6, KLH-IGF61-70, KLH-IGF1-16, KLH-IGF56-70, KLH-IGF30-38, KLH-IGF61-70, KLH-IGF29-42, KLH-IGF56-70, Qβ-IGF28-41, Qβ-IGF22-33, Qβ-IGF30-38, Qβ-IGF29-42, Qβ-IGF22-35, Qβ-IGF1-6, Qβ-IGF61-70, Qβ-IGF1-16, Qβ-IGF56-70, Qβ-IGF30-38, Qβ-IGF61-70, Qβ-IGF29-42 and Qβ-IGF56-70.

### Claim 20 (depends on 15)

The method of claim 15, wherein the antigen is a hydrolysis transition state analog of IGF-1 protein or an immunogenic portion thereof.

### Claim 21 (depends on 15)

The method of claim 15, wherein said reduction in tumor growth is accompanied by a decrease in tumor size.

### Claim 22 (depends on 15)

The method of claim 15, wherein the antigen is encoded in a nucleotide sequence and said nucleotide sequence is administered to said adult human.

### Claim 23

A method for treating or preventing cancer, the method comprising:
a) providing a human or humanized antibody, RNA Spiegelmer, or selective peptide which specifically binds to human IGF-1 when administered to a human under conditions appropriate for direct contact with endogenous IGF-1;
b) repeating as necessary to maintain circulating levels of the human or humanized antibody at levels sufficient to substantially reduce IGF-1-mediated stimulatory growth signals thereby resulting in the treatment or prevention of cancer.

### Claim 24 (depends on 23)

The method of claim 23, wherein the antibody is a monoclonal antibody.

### Claim 25 (depends on 23)

The method of claim 23, wherein the antibody is a single chain Fv antibody.

### Claim 26

A method for increasing longevity as measured by reducing one or more symptoms of aging in an adult warm blooded animal, comprising administering one or more of antibodies, RNA Spiegelmers, or selective peptides which specifically bind to IGF-1 to the animal such that IGF-1-mediated signaling is inactivated or suppressed and one or more symptoms of aging is reduced.

### Claim 27 (depends on 26)

The method of claim 26, further comprising repeating as necessary to maintain circulating levels of the antibodies in the blood.

### Claim 28 (depends on 26)

The method of claim 26, wherein the antibodies are monoclonal antibodies.

### Claim 29 (depends on 26)

The method of claim 26, wherein the antibodies are single chain Fv antibodies.

### Claim 30 (depends on 26)

The method of claim 26, wherein the antibodies are specific to a hydrolysis transition state analog of IGF-1 peptide or an immunogenic portion thereof.

### Claim 31 (depends on 26)

The method of claim 26, wherein the antibodies are specific to a native IGF-1 peptide or an immunogenic portion thereof.

### Claim 32 (depends on 26)

The method of claim 26 wherein the antibodies specifically interfere with the receptor-binding epitopes of IGF-1.

### Claim 33 (depends on 26)

The method of claim 26, wherein said antigen is encoded by a nucleic acid.

### Claim 34

A method increasing longevity as measured by reducing one or more symptoms of aging in an adult warm blooded animal, the method comprising:
a) providing one or more antigens the antigen characterized by the ability to stimulate the production of circulating antibodies which specifically bind to IGF-1 when administered to the animal under conditions appropriate for the stimulation of an immune response;
b) administering the antigen to the animal under conditions appropriate for the stimulation of an immune response, thereby stimulating the production of endogenous circulating antibodies which specifically bind to IGF-1 and one or more symptoms of aging is reduced.

### Claim 35 (depends on 34)

The method of claim 34, wherein the antigen is IGF-1 protein of an immunogenic portion thereof.

### Claim 36 (depends on 34)

The method of claim 34, wherein the antigen is a hydrolysis transition state analog of IGF-1 protein or an immunogenic portion thereof.

### Claim 37 (depends on 34)

The method of claim 34, wherein the antigen is selected from one or more of LPV-IGF1-16, LPV-IGF22-35, LPV-IGF29-42, LPV-IGF56-70, KLH-IGF28-41, KLH-IGF22-33, KLH-IGF30-38, KLH-IGF29-42, KLH-IGF22-35, KLH-IGF1-6, KLH-IGF61-70, KLH-IGF1-16, KLH-IGF56-70, KLH-IGF30-38, KLH-IGF61-70, KLH-IGF29-42, KLH-IGF56-70, Qβ-IGF28-41, Qβ-IGF22-33, Qβ-IGF30-38, Qβ-IGF29-42, Qβ-IGF22-35, Qβ-IGF1-6, Qβ-IGF61-70, Qβ-IGF1-16, Qβ-IGF56-70, Qβ-IGF30-38, Qβ-IGF61-70, Qβ-IGF29-42 and Qβ-IGF56-70.

### Claim 38 (depends on 34)

The method of claim 34, wherein said antigen is encoded by a nucleic acid.
